The effect of new biosimilars in rheumatology and gastroenterology specialities on UK healthcare budgets: Results of a budget impact analysis
(2018)
Journal Article
Aladul, M. I., Fitzpatrick, R. W., & Chapman, S. R. (2019). The effect of new biosimilars in rheumatology and gastroenterology specialities on UK healthcare budgets: Results of a budget impact analysis. Research in Social and Administrative Pharmacy, 15(3), 310-317. https://doi.org/10.1016/j.sapharm.2018.05.009
Background: The approval of new biosimilars of infliximab, etanercept and adalimumab by the European Medicines Agency is expected to produce further cost savings to the healthcare system budget. Objectives: This study aimed to estimate the budg... Read More about The effect of new biosimilars in rheumatology and gastroenterology specialities on UK healthcare budgets: Results of a budget impact analysis.